Related Experiment Video
Updated: Apr 28, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma
Erick Riquelme1, Milind B Suraokar1, Jaime Rodriguez1
1Department of Translational Molecular Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
Introduction:
Malignant pleural mesothelioma (MPM) is a deadly disease with poor prognosis and few treatment options. We characterized and elucidated the roles of C-MYC and PVT1 involved in the pathogenesis of MPM.
Methods:
We used small interfering RNA (siRNA)-mediated knockdown in MPM cell lines to determine the effect of C-MYC and PVT1 abrogation on MPM cells undergoing apoptosis, proliferation, and cisplatin sensitivity. We also characterized the expression of microRNAs spanning the PVT1 region in MPM cell lines. Copy number analysis was measured by quantitative polymerase chain reaction and fluorescence in situ hybridization.
Results:
Copy number analysis revealed copy number gains (CNGs) in chromosomal region 8q24 in six of 12 MPM cell lines. MicroRNA analysis showed high miR-1204 expression in MSTO-211H cell lines with four copies or more of PVT1. Knockdown by siRNA showed increased PARP-C levels in MSTO-211H transfected with siPVT1 but not in cells transfected with siC-MYC. C-MYC and PVT1 knockdown reduced cell proliferation and increased sensitivity to cisplatin. Analysis of the expression of apoptosis-related genes in the MSTO-211H cell line suggested that C-MYC maintains a balance between proapoptotic and antiapoptotic gene expression, whereas PVT1 and, to a lesser extent, miR-1204 up-regulate proapoptotic genes and down-regulate antiapoptotic genes. Fluorescence in situ hybridization analysis of MPM tumor specimens showed a high frequency of both CNGs (11 of 75) and trisomy (three copies; 11 of 75) for the C-MYC locus.
Conclusion:
Our results suggest that C-MYC and PVT1 CNG promotes a malignant phenotype of MPM, with C-MYC CNG stimulating cell proliferation and PVT1 both stimulating proliferation and inhibiting apoptosis.
Insights
Copy number gains in C-MYC and PVT1 promote malignant pleural mesothelioma (MPM) by increasing cell proliferation and inhibiting apoptosis. Targeting these genes enhances cisplatin sensitivity in MPM cells.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited treatment options.
- Understanding the molecular drivers of MPM is crucial for developing new therapies.
Purpose of the Study:
- To investigate the roles of C-MYC and PVT1 in the pathogenesis of MPM.
- To determine the impact of C-MYC and PVT1 on MPM cell apoptosis, proliferation, and drug sensitivity.
Main Methods:
- Small interfering RNA (siRNA)-mediated knockdown of C-MYC and PVT1 in MPM cell lines.
- Copy number analysis using quantitative PCR and fluorescence in situ hybridization.
- MicroRNA expression profiling and analysis of apoptosis-related genes.
Main Results:
- Copy number gains (CNGs) of C-MYC and PVT1 were observed in MPM cell lines and tumor specimens.
- C-MYC and PVT1 knockdown reduced MPM cell proliferation and increased sensitivity to cisplatin.
- PVT1 and miR-1204 were found to regulate apoptosis-related gene expression.
Conclusions:
- CNGs in C-MYC and PVT1 contribute to the malignant phenotype of MPM.
- C-MYC promotes cell proliferation, while PVT1 enhances proliferation and inhibits apoptosis.
- Targeting C-MYC and PVT1 may represent a therapeutic strategy for MPM.
More Related Videos
Related Concept Videos
Induced Pluripotent Stem Cells
Somatic...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer

